Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Kaya Holdings, Inc. stock logo
KAYS
Kaya
$0.04
+34.5%
$0.04
$0.03
$0.09
$574K0.585,010 shs30,880 shs
NRIFF
Nuvo Pharmaceuticals
$0.75
$0.30
$0.87
$8.52M1.577,337 shs3,000 shs
Reliv' International, Inc. stock logo
RELV
Reliv' International
$3.85
$3.51
$2.50
$4.42
$6.72M-0.123,200 shs125 shs
Xenetic Biosciences Inc stock logo
XBIO
Xenetic Biosciences
$3.78
-1.8%
$4.08
$2.55
$5.97
$5.82M2.65,868 shs1,657 shs
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Kaya Holdings, Inc. stock logo
KAYS
Kaya
+4.29%-5.81%-18.89%-32.87%-46.52%
NRIFF
Nuvo Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
Reliv' International, Inc. stock logo
RELV
Reliv' International
0.00%+1.32%-3.75%-2.04%+5.48%
Xenetic Biosciences Inc stock logo
XBIO
Xenetic Biosciences
0.00%-0.26%-2.53%+16.67%-12.50%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Kaya Holdings, Inc. stock logo
KAYS
Kaya
N/AN/AN/AN/AN/AN/AN/AN/A
NRIFF
Nuvo Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Reliv' International, Inc. stock logo
RELV
Reliv' International
N/AN/AN/AN/AN/AN/AN/AN/A
Xenetic Biosciences Inc stock logo
XBIO
Xenetic Biosciences
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Kaya Holdings, Inc. stock logo
KAYS
Kaya
N/AN/AN/AN/A
NRIFF
Nuvo Pharmaceuticals
N/AN/AN/AN/A
Reliv' International, Inc. stock logo
RELV
Reliv' International
N/AN/AN/AN/A
Xenetic Biosciences Inc stock logo
XBIO
Xenetic Biosciences
2.00
HoldN/AN/A

Current Analyst Ratings

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Kaya Holdings, Inc. stock logo
KAYS
Kaya
$200K2.87$0.18 per share0.22($1.07) per share-0.04
NRIFF
Nuvo Pharmaceuticals
$52.41M0.00N/A0.82$1.59 per share0.00
Reliv' International, Inc. stock logo
RELV
Reliv' International
$35.06M0.19$0.09 per share44.53$6.36 per share0.61
Xenetic Biosciences Inc stock logo
XBIO
Xenetic Biosciences
$2.54M2.29N/AN/A$6.36 per share0.59

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Kaya Holdings, Inc. stock logo
KAYS
Kaya
$1.61M-$0.02N/AN/A821.43%-9.57%638.26%4/26/2024 (Estimated)
NRIFF
Nuvo Pharmaceuticals
$2.53M$0.0418.69N/AN/A-2.81%8.02%1.11%N/A
Reliv' International, Inc. stock logo
RELV
Reliv' International
-$440KN/AN/AN/A-0.61%-1.89%-1.31%N/A
Xenetic Biosciences Inc stock logo
XBIO
Xenetic Biosciences
-$4.14M-$2.75N/AN/AN/A-162.84%-36.43%-33.74%5/9/2024 (Estimated)

Latest RELV, KAYS, XBIO, and NRIFF Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
4/16/2024Q4 2023
Kaya Holdings, Inc. stock logo
KAYS
Kaya
N/A$0.01+$0.01$0.01N/A$0.03 million
3/21/2024Q4 2023
Xenetic Biosciences Inc stock logo
XBIO
Xenetic Biosciences
-$0.87-$0.77+$0.10-$0.77$0.68 million$0.67 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Kaya Holdings, Inc. stock logo
KAYS
Kaya
N/AN/AN/AN/AN/A
NRIFF
Nuvo Pharmaceuticals
N/AN/AN/AN/AN/A
Reliv' International, Inc. stock logo
RELV
Reliv' International
N/AN/AN/AN/AN/A
Xenetic Biosciences Inc stock logo
XBIO
Xenetic Biosciences
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Kaya Holdings, Inc. stock logo
KAYS
Kaya
N/A
0.01
0.01
NRIFF
Nuvo Pharmaceuticals
5.27
2.67
2.11
Reliv' International, Inc. stock logo
RELV
Reliv' International
0.05
1.70
1.04
Xenetic Biosciences Inc stock logo
XBIO
Xenetic Biosciences
N/A
11.84
11.84

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Kaya Holdings, Inc. stock logo
KAYS
Kaya
N/A
NRIFF
Nuvo Pharmaceuticals
N/A
Reliv' International, Inc. stock logo
RELV
Reliv' International
7.95%
Xenetic Biosciences Inc stock logo
XBIO
Xenetic Biosciences
15.12%

Insider Ownership

CompanyInsider Ownership
Kaya Holdings, Inc. stock logo
KAYS
Kaya
23.52%
NRIFF
Nuvo Pharmaceuticals
N/A
Reliv' International, Inc. stock logo
RELV
Reliv' International
31.18%
Xenetic Biosciences Inc stock logo
XBIO
Xenetic Biosciences
9.00%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Kaya Holdings, Inc. stock logo
KAYS
Kaya
414.72 million11.26 millionNot Optionable
NRIFF
Nuvo Pharmaceuticals
9911.40 millionN/ANot Optionable
Reliv' International, Inc. stock logo
RELV
Reliv' International
911.75 millionN/ANot Optionable
Xenetic Biosciences Inc stock logo
XBIO
Xenetic Biosciences
41.54 million1.40 millionNot Optionable

RELV, KAYS, XBIO, and NRIFF Headlines

SourceHeadline
Xenetic Biosciences Inc (XBIO)Xenetic Biosciences Inc (XBIO)
investing.com - April 10 at 3:28 PM
Xenetic Biosciences Full Year 2023 Earnings: EPS Beats Expectations, Revenues LagXenetic Biosciences Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag
finance.yahoo.com - March 24 at 5:09 PM
Xenetic Dips on Full-Year ResultsXenetic Dips on Full-Year Results
baystreet.ca - March 22 at 7:33 PM
Xenetic Biosciences reports FY resultsXenetic Biosciences reports FY results
msn.com - March 22 at 8:51 AM
Xenetic Biosciences, Inc. Reports Full Year 2023 Financial ResultsXenetic Biosciences, Inc. Reports Full Year 2023 Financial Results
accesswire.com - March 22 at 8:00 AM
Xenetic to advance DNase programme with UVA partnershipXenetic to advance DNase programme with UVA partnership
msn.com - January 18 at 1:37 PM
Xenetic Biosciences Inc XBIOXenetic Biosciences Inc XBIO
morningstar.com - January 4 at 5:10 PM
Xenetic Biosciences Stock (NASDAQ:XBIO), Guidance and ForecastXenetic Biosciences Stock (NASDAQ:XBIO), Guidance and Forecast
benzinga.com - December 11 at 9:01 AM
Most Shareholders Will Probably Agree With Xenetic Biosciences, Inc.s (NASDAQ:XBIO) CEO CompensationMost Shareholders Will Probably Agree With Xenetic Biosciences, Inc.'s (NASDAQ:XBIO) CEO Compensation
finance.yahoo.com - November 30 at 10:39 AM
Xenetic Biosciences: Q3 Earnings InsightsXenetic Biosciences: Q3 Earnings Insights
benzinga.com - November 10 at 3:38 PM
MediciNova: Q3 Earnings SnapshotMediciNova: Q3 Earnings Snapshot
washingtonpost.com - November 10 at 10:37 AM
Xenetic Biosciences, Inc. to Participate at the Virtual Investor Ask the CEO ConferenceXenetic Biosciences, Inc. to Participate at the Virtual Investor Ask the CEO Conference
finance.yahoo.com - October 11 at 9:30 AM
Xenetic Biosciences (XBIO) Upgraded to Strong Buy: What Does It Mean for the Stock?Xenetic Biosciences (XBIO) Upgraded to Strong Buy: What Does It Mean for the Stock?
msn.com - July 13 at 1:44 PM
Xenetic Biosciences, Inc. Reports First Quarter 2023 Financial Results and Provides Business UpdateXenetic Biosciences, Inc. Reports First Quarter 2023 Financial Results and Provides Business Update
finance.yahoo.com - May 11 at 5:06 PM
Xenetic Biosciences, Inc. Adds Business Development Expertise with Appointment of Scott N. Cullison | MorningstarXenetic Biosciences, Inc. Adds Business Development Expertise with Appointment of Scott N. Cullison | Morningstar
morningstar.com - May 5 at 10:21 AM
Xenetic Biosciences, Inc. Bolsters R&D and Regulatory Expertise with Appointment of Reid P. Bissonnette, Ph.D. as Executive Consultant for Translational Research and DevelopmentXenetic Biosciences, Inc. Bolsters R&D and Regulatory Expertise with Appointment of Reid P. Bissonnette, Ph.D. as Executive Consultant for Translational Research and Development
finance.yahoo.com - May 4 at 10:02 AM
Xenetic Biosciences, Inc. Adds Business Development Expertise with Appointment of Scott N. CullisonXenetic Biosciences, Inc. Adds Business Development Expertise with Appointment of Scott N. Cullison
finance.yahoo.com - May 3 at 10:26 AM
HC Wainwright & Co. Reiterates Xenetic Biosciences (XBIO) Buy RecommendationHC Wainwright & Co. Reiterates Xenetic Biosciences (XBIO) Buy Recommendation
msn.com - April 12 at 10:37 PM
Xenetic Biosciences forms research collaboration with TSRIXenetic Biosciences forms research collaboration with TSRI
pharmaceutical-technology.com - April 12 at 12:36 PM
Analysts Offer Insights on Healthcare Companies: Adaptimmune Therapeutics (ADAP) and Xenetic Biosciences (XBIO)Analysts Offer Insights on Healthcare Companies: Adaptimmune Therapeutics (ADAP) and Xenetic Biosciences (XBIO)
markets.businessinsider.com - April 12 at 2:30 AM
Xenetic Biosciences, Inc. Announces Research and Development Collaboration with The Scripps Research Institute to Advance DNase PlatformXenetic Biosciences, Inc. Announces Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform
finance.yahoo.com - April 11 at 8:43 AM
JTC Team, LLC: JTC Team to Host Virtual Investor NETs in Cancer Spotlight Event Featuring Xenetic BiosciencesJTC Team, LLC: JTC Team to Host Virtual Investor NETs in Cancer Spotlight Event Featuring Xenetic Biosciences
finanznachrichten.de - March 16 at 12:09 PM
JTC Team to Host Virtual Investor NETs in Cancer Spotlight Event Featuring Xenetic BiosciencesJTC Team to Host Virtual Investor NETs in Cancer Spotlight Event Featuring Xenetic Biosciences
finance.yahoo.com - March 16 at 12:09 PM
XBIO Xenetic Biosciences, Inc.XBIO Xenetic Biosciences, Inc.
seekingalpha.com - February 23 at 11:29 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Kaya logo

Kaya

OTCMKTS:KAYS
Kaya Holdings, Inc., a vertically integrated legal cannabis enterprise, produces, distributes, and/or sells a range of cannabis products primarily in the United States. The company offers flower, oils, vape cartridges and cannabis infused confections, baked goods, and beverages. It also operates retail outlets under the Kaya Shack brand name, as well as offers strain specific cannabis cigarettes under the Kaya Buddies name, and strains of cannabis under the Kaya Farms name. In addition, the company provides standing display cases with cannabis intended glassware under the Really Happy Glass brand; and t-shirt designs under the Kaya Gear brand name. The company was formerly known as Alternative Fuels America, Inc. and changed its name to Kaya Holdings, Inc. in April 2015. Kaya Holdings, Inc. was incorporated in 1993 and is headquartered in Fort Lauderdale, Florida.

Nuvo Pharmaceuticals

OTCMKTS:NRIFF
Nuvo Pharmaceuticals, Inc. is a pharmaceutical company, which is engaged in developing innovative therapeutic pharmaceutical products. It operates through the following segments: Commercial Business, Production and Service Business and Licensing and Royalty Business. The Commercial Business segment includes Blexten, Cambia, the canadian business for Resultz and Suvexx, and mature assets. The Production and Service Business segment supplies Pennsaid to Horizon for the U.S. market and is engaged in ongoing partnering efforts for Pennsaid. The Licensing and Royalty Business segment engages in the selling of Vimovo. Nuvo Pharmaceuticals was founded on August 22, 1983 and is headquartered in Mississauga, Canada.
Reliv

Reliv' International

NASDAQ:RELV
Reliv' International, Inc. develops and markets nutritional supplements that address basic nutrition, specific wellness needs, weight management, and sports nutrition. The company's basic nutritional supplements are formulated to provide a balanced and complete level of supplementation for the consumer. Its principal products include Reliv Classic, Reliv Now, Innergize!, and FibRestore along with LunaRich X capsules. The company markets and sells its products through a direct selling system of independent distributors in the United States, Australia, Austria, Canada, France, Germany, Indonesia, Ireland, Malaysia, Mexico, the Netherlands, New Zealand, the Philippines, and the United Kingdom. Reliv' International, Inc. was founded in 1988 and is headquartered in Chesterfield, Missouri.
Xenetic Biosciences logo

Xenetic Biosciences

NASDAQ:XBIO
Xenetic Biosciences, Inc. is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications.